My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Xenetic Biosciences, Inc. - Common Stock (NQ:XBIO)

10.30 -0.06 (-0.58%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 216,262
Open 10.30
Bid (Size) 9.160 (2)
Ask (Size) 9.500 (5)
Prev. Close 10.36
Today's Range 10.30 - 10.30
52wk Range 2.200 - 13.93
Shares Outstanding 1,542,139
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Richardson Electronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
MAGA Stocks Undercard: MYSE, XBIO, ATON, ACXP, RDZN – Innovators Driving Next Tech, Blockchain, AI Wave – More Stocks Inside
Via AB Newswire
Topics Artificial Intelligence Intellectual Property

Performance

YTD
+154.3%
+154.3%
1 Month
+237.7%
+237.7%
3 Month
+150.6%
+150.6%
6 Month
+325.6%
+325.6%
1 Year
+151.8%
+151.8%

More News

Read More
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Via ACCESSWIRE
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Via ACCESSWIRE
Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results
Via ACCESSWIRE
Nasdaq Gains 150 Points; US Mortgage Applications Decline
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Confluent Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results
Via ACCESS Newswire
Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma
Via ACCESS Newswire
Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
Via ACCESS Newswire
Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic
Via ACCESS Newswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
Via ACCESS Newswire
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Via ACCESS Newswire
Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma
Via ACCESS Newswire
Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results
Via ACCESS Newswire
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses
Via ACCESS Newswire
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting
Via ACCESS Newswire
Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform
Via ACCESSWIRE
Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program
Via ACCESSWIRE
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis
Via ACCESSWIRE
Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models
Via ACCESSWIRE

Frequently Asked Questions

Is Xenetic Biosciences, Inc. - Common Stock publicly traded?
Yes, Xenetic Biosciences, Inc. - Common Stock is publicly traded.
What exchange does Xenetic Biosciences, Inc. - Common Stock trade on?
Xenetic Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Xenetic Biosciences, Inc. - Common Stock?
The ticker symbol for Xenetic Biosciences, Inc. - Common Stock is XBIO on the Nasdaq Stock Market
What is the current price of Xenetic Biosciences, Inc. - Common Stock?
The current price of Xenetic Biosciences, Inc. - Common Stock is 10.30
When was Xenetic Biosciences, Inc. - Common Stock last traded?
The last trade of Xenetic Biosciences, Inc. - Common Stock was at 10/08/25 04:00 PM ET
What is the market capitalization of Xenetic Biosciences, Inc. - Common Stock?
The market capitalization of Xenetic Biosciences, Inc. - Common Stock is 15.88M
How many shares of Xenetic Biosciences, Inc. - Common Stock are outstanding?
Xenetic Biosciences, Inc. - Common Stock has 16M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.